The Use Of Daily Continuous Glucose Monitoring (Chmg) In Clinical Practice

Type 1 diabetes mellitus is a disease in which the highest rates of premature mortality and early disability of patients are observed, which is caused by the onset of the disease at an early age, the instability of the course of type 1 diabetes and the threat of acute and chronic complications. The goals of type 1 diabetes mellitus treatment are its compensation, prevention of the risk of complications when normoglycemia is reached and stabilized.


INTRODUCTION
Relevance of the problem:. Diabetes mellitus in recent decades has been one of the first priorities of national health systems in all countries of the world, due to the high prevalence of this pathology and the growth of socio-economic losses associated with the development of severe disabling complications.
In 2014, the number of patients with diabetes mellitus in the world, according to WHO experts, amounted to more

The Use Of Daily Continuous Glucose Monitoring (Chmg) In Clinical Practice
The American Journal of Medical Sciences and Pharmaceutical Research (ISSN -2689-1026) Published: September 29, 2020 | Pages: 82-85 Doi: https://doi.org/10.37547/TAJMSPR/Volume02Issue09-17 IMPACT FACTOR 2020: 5. 286 than 360 million people, by 2030, it is expected to increase the number of patients to 480 million people. Self-monitoring of blood glucose is the primary way to control and manage diabetes. The current ADA (American Nutritional Association) recommendations imply that a patient with diabetes mellitus self-monitors blood glucose levels at least 4 times a day (3 times before meals and 1 time before bedtime).
Target: The aim of this work was to develop a continuous monitoring system (LMWH) of blood glucose in the management of type 1 diabetes mellitus using a pump. The CGM system was the first device approved by the FDA for three-day monitoring.

MATERIALS AND RESEARCH METHODS
The study was carried out on the basis of the Department of Endocrinology at the Samarkand Regional Endocrinological Dispensary. The study included 31 patients with type 1 diabetes mellitus, 36% (n-12) men and 64% (n-19) women. The duration of the disease ranged from 6 months to 25 years (on average, 13.24 + 2.59 years). The patients' age ranged from 15 to 45 years (average 29 + 3.26 years). Pear 1 -patients who received insulin therapy in the mode of continuous subcutaneous insulin administration using an insulin pump (9 person). Pear 2 (control)patients who continued to receive a combination of insulin glargine (Lantus) plus ultrashort-acting human insulin analogues (22 people). The presence of complications of diabetes mellitus was determined according to the data of narrow specialists, as well as on the basis of biochemical blood tests. The inclusion criteria were: an established diagnosis of type 1 diabetes mellitus in the stage of decompensation, the presence of motivation and the ability to follow the doctor's recommendations.
Group 2, whose patients received conventional insulin therapy in a multiple-injection regimen, was considered as a comparison bulb, which made it possible to evaluate the advantages of different methods of insulin therapy. Therefore, a comparative analysis of the parameters of carbohydrate metabolism according to the data of selfcontrol and continuous daily monitoring in group 2 and their comparison with the corresponding indicators of group 1 was of particular interest. The average total glycemic value decreased from 10.81-0.04 to 9.04 + 0.04 mmol / L (p <0.05), there was a significant decrease in the postprandial average glycemic value from 12.3 + 0.18 to 9.92+ 0.18 mmol / L (p-0.05). The glycated hemoglobin (HbAlc) value decreased after 6 months. therapy, however, without reaching the target level, and amounted to 8.30 + 0.04% (w-0. Results and discussion. 1. The use of NPVI in patients with type 1 diabetes mellitus provides less variability in the level of glycemia due to a decrease in the number of peaks-fluctuations in comparison with the regimen of multiple insulin injections, reduces the duration of episodes of hypo-and hyperglycemia, and significantly increases the duration of the period of normoglycemia to 87.3% when monitored with using a continuous glycemic monitoring system (CGM) for 72 hours.
2. On the background of therapy with an insulin pump, the target HbAlc values were achieved in 42.8% of patients, 57.2% of patients showed a decrease in HbAlc levels. In patients on a regimen of repeated insulin injections, the HbAlc value also decreases, however, not reaching the target value.